Archives of Nephrology and Renal Studies

Case Report Open Access

Intervention of Atypical Hemolytic Uremic Syndrome with Eculizumab within Seven Days Resulting in Near Normalization of Hematologic and Renal Parameters: A Case Report Supporting Recent Real-World Evidence

Madhu Parna Chakrabarti , Shuvendu Sen

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA) caused by complement dysregulation, often leading to end-stage renal disease and death. Recent real-world and post-marketing surveillance studies underscore the critical importance of initiating eculizumab, a terminal complement inhibitor, within seven days of disease onset, which is associated with sustained inhibition of TMA and marked improvement in renal outcomes and survival compared with delayed treatment. 

Arch Nephrol Ren Stud, 2026, Volume 6, Issue 1, p1-6 | DOI: 10.33696/nephrology.6.016